We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Icosapent Ethyl (Vascepa)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Icosapent Ethyl (Vascepa) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2011–2025 with a typical study size of 8,179 participants.
Based on 7 studies · 1 meta-analysis · 5 RCTs · 29,436 total participants
Confidence
HighBy outcome
Icosapent Ethyl (Vascepa) has an evidence score of 4.2/10 — strong evidence based on 7 indexed studies, including 1 meta-analysis. A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement. Representative study: PMID 35290840.
The commonly studied dose of Icosapent Ethyl (Vascepa) is Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Nicotinamide Riboside
Mostly mechanism / observationalA vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Alirocumab (Praluent)
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Icosapent Ethyl (Vascepa / Vazkepa) — purified EPA ethyl ester
A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement.
Icosapent ethyl has one large, well-powered outcome trial (REDUCE-IT) showing a ~25% reduction in major cardiovascular events in statin-treated high-triglyceride patients, plus consistent triglyceride-lowering RCTs (MARINE, ANCHOR). But the mechanism of the cardiovascular benefit is debated, the mineral-oil comparator may have inflated the effect, a contrasting omega-3 trial (STRENGTH) showed no benefit, and the drug modestly raises atrial fibrillation and bleeding risk — so the evidence is strong but not unambiguous, and it does NOT generalize to OTC fish oil.
Icosapent ethyl (Vascepa in the US, Vazkepa in the EU; trial name AMR101) is a prescription omega-3 — a highly purified ethyl ester of eicosapentaenoic acid (EPA) only, containing no DHA. This is the crucial distinction from OTC fish-oil capsules, which are mixed EPA/DHA at far lower doses.
Taken at 4 g/day with food, it lowers triglycerides (~20–35% in hypertriglyceridemic patients in the MARINE and ANCHOR trials) and has pleiotropic effects beyond lipid-lowering: membrane stabilization, anti-inflammatory and antioxidant activity, and improved endothelial function.
Its landmark evidence is REDUCE-IT (Bhatt 2019, NEJM), a randomized trial of ~8,200 statin-treated patients with elevated triglycerides and high cardiovascular risk, which showed a significant ~25% relative reduction in major adverse cardiovascular events (cardiovascular death, MI, stroke, revascularization, unstable angina).
That is a genuinely large, prospective outcome benefit — rare for a lipid-adjacent therapy.
The honest complications: (1) the magnitude of benefit exceeds what triglyceride-lowering alone explains, so the true mechanism is debated; (2) the comparator in REDUCE-IT was mineral oil, which mildly raised LDL/CRP in the placebo arm and may have inflated the apparent benefit; (3) a separate large trial of a mixed EPA/DHA omega-3 (STRENGTH, Nicholls 2020, JAMA) against a corn-oil placebo found NO cardiovascular benefit, as did several fish-oil supplement trials (e.g.
VITAL) — so the benefit is specific to high-dose purified EPA, not omega-3 supplements generally; and (4) icosapent ethyl modestly increases the risk of atrial fibrillation and of serious bleeding.
The score reflects one strong, well-powered outcome trial and consistent triglyceride-lowering data, tempered by the unresolved mechanism/comparator debate and real arrhythmia and bleeding trade-offs.
This is a prescription drug for a defined clinical population — it is not a substitute for, nor equivalent to, an over-the-counter fish-oil supplement.
EPA reduces hepatic VLDL-triglyceride production and enhances clearance, lowering plasma triglycerides ~20–35% at 4 g/day — most in patients with high baseline levels.
EPA incorporates into cell membranes, providing antioxidant, membrane-stabilizing, anti-inflammatory, and endothelial effects proposed to explain cardiovascular benefit beyond lipid-lowering.
EPA is a substrate for specialized pro-resolving mediators and lowers inflammatory signaling, contributing to plaque stabilization in the proposed (but debated) mechanism.
How Icosapent Ethyl (Vascepa) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Approved dose is 2 g twice daily (4 g/day total) taken with food, under a clinician, for statin-treated adults with elevated triglycerides and high cardiovascular risk. A prescription drug — not a self-directed regimen.
Loading: No loading dose; the full 4 g/day dose is used from initiation, split as 2 g twice daily with meals.
Take with food
| Form | Type |
|---|---|
| 💊Oral capsule — purified EPA ethyl ester (icosapent ethyl) | Recommended |
| 💊Mixed EPA/DHA omega-3 acid prescriptions (different evidence base; STRENGTH showed no CV benefit) | Alternative |
Icosapent ethyl is EPA-only and carries the REDUCE-IT outcome data. OTC fish-oil and mixed EPA/DHA products are NOT equivalent.
Minimum: 12 weeks
Optimal: 52 weeks
Cycling: Not required
Note: 2 g twice daily with meals. Absorption is better with food; swallow capsules whole.
Dose-response data unavailable. The current published research for Icosapent Ethyl (Vascepa) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
In REDUCE-IT, cut the composite of cardiovascular death, MI, stroke, revascularization, and unstable angina by ~25% in statin-treated high-risk patients.
Lowers triglycerides ~20–35% at 4 g/day, including on top of statins (ANCHOR) and in very high-triglyceride patients (MARINE).
Reduces inflammatory markers and improves membrane stability — part of the proposed pleiotropic benefit beyond lipid-lowering.
Modestly increases the risk of new-onset atrial fibrillation and of serious bleeding — a consistent trade-off seen in REDUCE-IT and real-world data.
Benefit exceeds what TG-lowering explains and the mineral-oil comparator may have inflated it; a mixed EPA/DHA omega-3 trial (STRENGTH) showed no benefit — so this is NOT the same as taking OTC fish oil.
Use with caution — the AF signal is concentrated in those with a prior history; monitor rhythm.
Monitor for bleeding; the combination raises bleeding risk, especially perioperatively.
Not a self-directed swap — it is a prescription drug for a defined high-risk population, and OTC fish oil did not show the same benefit.
Additive bleeding risk; icosapent ethyl can prolong bleeding time.
Icosapent ethyl modestly increases atrial fibrillation risk; monitor in patients with prior AF.
Tip: Higher in patients with prior AF; monitor for palpitations and report them. Seen consistently in REDUCE-IT and real-world data.
Tip: Risk is amplified by concurrent antithrombotics; watch for unusual bruising/bleeding, especially around procedures.
Tip: Generally mild and tolerable; taking with food can reduce GI complaints.
The best time to take Icosapent Ethyl (Vascepa) is with meals. Take it with food. Taken with food to maximize absorption of the lipophilic ethyl ester; split as 2 g twice daily.
Icosapent Ethyl (Vascepa) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are new-onset atrial fibrillation / flutter, bleeding (including serious bleeding), musculoskeletal pain / peripheral edema / constipation. Use caution if any of these apply to you: Known hypersensitivity to icosapent ethyl or its components; Caution with fish/shellfish allergy (limited data); Active serious bleeding.
A fully human monoclonal-antibody PCSK9 inhibitor (Praluent), injected under the skin every 2 weeks, that lowers LDL cholesterol by ~50–60%. In the ODYSSEY OUTCOMES trial of ~18,900 post-heart-attack patients it reduced major cardiovascular events and showed a possible all-cause mortality signal. Generally well tolerated; injection-site reactions and high cost/access are the main trade-offs. Prescription drug, not a supplement.